| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $21,007,362 | 42 | 100 |
| Goodrich Katherine | director | 0 | $0 | 1 | $183,384 | $-183,384 |
| Wahl Bryan | General Counsel | 0 | $0 | 3 | $850,417 | $-850,417 |
| Mottiwala Aziz | Chief Commercial Officer | 0 | $0 | 3 | $892,528 | $-892,528 |
| Farrow Jeffrey S | See Remarks | 0 | $0 | 4 | $1.32M | $-1.32M |
| Neervannan Seshadri | Chief Operating Officer | 0 | $0 | 6 | $2M | $-2M |
| Lin Elizabeth Yeu | Chief Medical Officer | 0 | $0 | 8 | $2.96M | $-2.96M |
| Whitfield Dianne C. | Chief Human Resources Officer | 0 | $0 | 6 | $3.14M | $-3.14M |
| LINK WILLIAM J PHD | director | 0 | $0 | 4 | $4.48M | $-4.48M |
| Azamian Bobak R. | President/CEO and Board Chair | 0 | $0 | 7 | $5.18M | $-5.18M |
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A …
Over the last 12 months, insiders at Tarsus Pharmaceuticals, Inc. have bought $0 and sold $21.01M worth of Tarsus Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Tarsus Pharmaceuticals, Inc. have bought $1.06M and sold $9.2M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $18,960 was made by Goldberg Andrew D. (director) on 2023‑12‑15.
| 2026-09-15 | Sale | LINK WILLIAM J PHD | director | 12,500 0.0291% | $78.38 | $979,744 | -5.91% | |
| 2026-09-04 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 10,000 0.023% | $90.56 | $905,600 | -18.16% | |
| 2026-09-04 | Sale | Neervannan Seshadri | Chief Operating Officer | 4,564 0.0098% | $85.00 | $387,940 | -18.16% | |
| 2026-09-04 | Sale | Lin Elizabeth Yeu | Chief Medical Officer | 6,977 0.0151% | $85.00 | $593,045 | -18.16% | |
| 2026-09-04 | Sale | Lin Elizabeth Yeu | Chief Medical Officer | 13,953 0.031% | $87.50 | $1.22M | -18.16% | |
| 2026-09-02 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 10,000 0.0225% | $80.06 | $800,600 | -10.10% | |
| 2026-09-02 | Sale | Lin Elizabeth Yeu | Chief Medical Officer | 6,977 0.0157% | $80.00 | $558,160 | -10.10% | |
| 2026-09-01 | Sale | Lin Elizabeth Yeu | Chief Medical Officer | 4,601 0.0107% | $73.86 | $339,830 | +0.51% | |
| 2026-06-17 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 10,000 0.0229% | $61.55 | $615,488 | +13.17% | |
| 2026-06-16 | Sale | Farrow Jeffrey S | See Remarks | 14,396 0.0335% | $60.95 | $877,436 | +16.38% | |
| 2026-06-15 | Sale | LINK WILLIAM J PHD | director | 12,500 0.0292% | $62.12 | $776,495 | +14.32% | |
| 2026-06-15 | Sale | Goodrich Katherine | director | 2,954 0.0069% | $62.08 | $183,384 | +14.32% | |
| 2026-03-20 | Sale | Neervannan Seshadri | Chief Operating Officer | 2,989 0.0073% | $66.75 | $199,516 | +3.94% | |
| 2026-03-19 | Sale | Neervannan Seshadri | Chief Operating Officer | 4,589 0.0108% | $67.00 | $307,463 | +0.38% | |
| 2026-03-19 | Sale | Wahl Bryan | General Counsel | 4,231 0.01% | $67.00 | $283,477 | +0.38% | |
| 2026-03-19 | Sale | Mottiwala Aziz | Chief Commercial Officer | 4,440 0.0105% | $67.00 | $297,480 | +0.38% | |
| 2026-03-19 | Sale | Farrow Jeffrey S | See Remarks | 2,186 0.0052% | $67.00 | $146,462 | +0.38% | |
| 2026-03-19 | Sale | Whitfield Dianne C. | Chief Human Resources Officer | 4,174 0.0098% | $67.00 | $279,658 | +0.38% | |
| 2026-03-19 | Sale | Azamian Bobak R. | President/CEO and Board Chair | 11,964 0.0282% | $67.00 | $801,588 | +0.38% | |
| 2026-03-19 | Sale | Lin Elizabeth Yeu | Chief Medical Officer | 390 0.0009% | $67.00 | $26,130 | +0.38% |
| Lin Elizabeth Yeu | Chief Medical Officer | 1590 0.0034% | $115,497.60 | 2 | 9 | +27.05% |
| Vivo Capital IX, LLC | 10 percent owner | 2469001 5.2766% | $179.35M | 1 | 10 | +36.85% |
| Tester Jason E. | 1920933 4.1053% | $139.54M | 1 | 0 | +36.85% | |
| Horowitz Limited Partnership VIII | 10 percent owner | 1920933 4.1053% | $139.54M | 1 | 0 | +36.85% |
| Frazier Life Sciences IX, L.P. | 10 percent owner | 1917157 4.0972% | $139.26M | 1 | 0 | +36.85% |
| Ackermann Michael | 100000 0.2137% | $7.26M | 1 | 9 | +25.23% | |
| Goldberg Andrew D. | director | 3000 0.0064% | $217,920.00 | 1 | 0 | +69.5% |
$52,263,649 | 70 | 1.18% | $2.49B | |
$104,428,685 | 44 | 22.55% | $3.78B | |
$1,275,975,557 | 32 | 19.44% | $3.54B | |
$151,136,640 | 31 | -1.41% | $3.95B | |
$5,066,938 | 27 | 26.38% | $3.7B |
| Increased Positions | 141 | +57.09% | 5M | +11.08% |
| Decreased Positions | 111 | -44.94% | 6M | -13.48% |
| New Positions | 55 | New | 2M | New |
| Sold Out Positions | 24 | Sold Out | 2M | Sold Out |
| Total Postitions | 277 | +12.15% | 44M | -2.4% |
| Blackrock, Inc. | $305,280.00 | 9% | 3.78M | -12,564 | -0.33% | 2025-09-30 |
| Rtw Investments, Lp | $256,642.00 | 7.57% | 3.18M | +65,756 | +2.11% | 2025-09-30 |
| Deep Track Capital, Lp | $242,310.00 | 7.14% | 3M | +1M | +71.43% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $215,308.00 | 6.35% | 2.67M | -310,401 | -10.43% | 2025-09-30 |
| Jennison Associates Llc | $210,372.00 | 6.2% | 2.6M | +136,582 | +5.53% | 2025-09-30 |
| Tang Capital Management Llc | $198,274.00 | 5.85% | 2.45M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $183,517.00 | 5.41% | 2.27M | -25,264 | -1.1% | 2025-09-30 |
| Morgan Stanley | $154,465.00 | 4.55% | 1.91M | -143,316 | -6.97% | 2025-09-30 |
| Janus Henderson Group Plc | $116,228.00 | 3.43% | 1.44M | -367,948 | -20.36% | 2025-09-30 |
| Assenagon Asset Management S.A. | $100,797.00 | 2.97% | 1.25M | +250,367 | +25.1% | 2025-09-30 |